Alpha-1 Antitrypsin Deficiency

The clinical effects of alpha-1 antitrypsin deficiency (AATD) are highly variable and are dependent on genotype, phenotype and exposure to risk factors such as smoking and pollution.1,2

AATD is a genetic condition associated with low protein levels of functional alpha-1 proteinase inhibitor (A1PI).2,3

The main clinical manifestations involve the lungs, leading to emphysema, and the liver, but it can also be associated with other skin and cardiovascular disorders.3,4,5

Pathophysiology

AATD is caused by a mutation in the SERPINA1 gene on chromosome 14 encoding for A1PI.6 Each person has two alleles (variants) of the gene, one inherited from each parent where the most common ones are:5

  • M allele— results in normal levels of functional A1PI6,7
  • S allele—  expresses approximately 50 to 60% normal A1PI where the variant is unstable and easily degrades8,9
  • Z allele—  expresses approximately 10 to 20% of normal A1PI due to much of the A1PI accumulating in the liver8,9


A1PI is primarily synthesized in the liver and secreted into the bloodstream where it diffuses into the lungs and other tissues.2,8,10  The main role of A1PI is to inhibit neutrophil elastase (NE) and keep its activity in check.2,10 NE is a proteinase responsible for the breakdown of a variety of proteins involved in modulating inflammation and therefore plays a key role in tissue repair and protection from infections.11 Therefore, a deficiency in functional A1PI results in excessive NE activity and leads to the degradation of lung tissue and blood vessels.12

Epidemiology

The prevalence of AATD varies by genotype with an estimated 3.4 million people living with the disease worldwide (protease inhibitor [Pi] SS, PiSZ, PiZZ) and 116 million carriers (PiMS, PiMZ).2,13 In the U.S., it’s estimated that more than 500,000 people have deficient PiSS and PiSZ allele combinations, and 60,000 have the PiZZ genotype which is associated with severe deficiency, while more than 24 million people are carriers (PiMS, PiMZ).8

Diagnosis

Variability in clinical presentations results in delayed and misdiagnosis, which means the majority of cases remain undiagnosed (>90%).1,14,15,16 A confirmed AATD diagnosis should involve both quantitative and qualitative laboratory determinations:10,17,18,19

  • Quantitative determination of serum A1PI levels
  • Confirmatory qualitative assessment of genotyping/phenotyping
  • DNA sequencing may be necessary to identify rarer mutations

Navigating AATD

The primary manifestations of AATD are lung disease and liver involvement, which are irreversible and progressive.20 Therefore, the consequences of delayed or misdiagnosis can be fatal in those patients with severe AATD; most commonly due to respiratory failure (58% of deaths), including pneumonia and pneumothorax; and liver diseases (12% of deaths), including liver failure and primary carcinoma.21 This leads to a high disease burden, associated with increased mortality, morbidity, quality of life impairment and cost.21,22,23,24,25,26 Nonpharmacological approaches are crucial to managing AATD and include smoking cessation, maintaining a healthy diet and moderate exercise, staying up to date with recommended immunization and pulmonary rehabilitation.17 Currently, augmentation therapy is the only A1P1 pharmacological option available and can be part of the strategy in the management of patients with AATD-related emphysema.10,27,28 It is administered by intravenous infusion and aims to increase serum A1PI levels.2 However, the manufacturing process is complex and expensive to produce as it needs to be purified from large volumes of human plasma.29

Medication Resources

Aralast® NP

[Alpha1-Proteinase Inhibitor (Human)]

Glassia®

[Alpha1-Proteinase Inhibitor (Human)]

Upcoming & Past Conferences in Allergy & Immunology

  • Upcoming

  • Past

Western Society of Allergy, Asthma and Immunology (WSAAI), 2025

February 9 - 13, 2025 | Link to Event

Annual scientific session uniting allergists, immunologists, nurses, and physician assistants aimed at maintaining the highest standard of practice in allergy care.

Annual Meeting American Academy of Allergy Asthma and Immunology (AAAAI), 2025

February 28 - March 3, 2025 | Link to Event

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

American Academy of Neurology (AAN), 2025

April 5 - 9, 2025 | Link to Event

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

American College of Allergy, Asthma & Immunology (ACAAI), 2024

October 24 - 28, 2024

Global meeting featuring thought leaders from around the world focused on advancing patient care in allergy and immunology.

Immunoglobulin National Society (IgNS), 2024

October 17 - 20, 2024

National conference of IgNS bringing together professionals and practitioners from all disciplines and clinical specialties to advance Ig therapy practice, while providing networking and comprehensive education opportunities.

The European Society for Immunodeficiencies (ESID), 2024

October 16 - 19, 2024

Biennial meeting that covers the latest discoveries in basic and clinical science covering our expanding field, bringing together internationally renowned scientists and clinicians to present and discuss major developments in diagnosis, clinical management, genetics, and immunobiology of inborn errors of immunity.

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2024

October 15 - 18, 2024

Annual meeting dedicated to the advancement of neuromuscular, musculoskeletal, and electrodiagnostic  medicine.

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2024

October 14 - 17, 2024

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

American College of Chest Physicians (CHEST), 2024

October 6 - 9, 2024

Annual meeting offering the most up-to-date education in pulmonary, sleep, and critical care medicine through simulation sessions and original research presentations with clinical relevance to practitioners.

Neuromuscular Study Group (NMSG), 2024

September 20 - 22, 2024

Annual conference aiming to advance knowledge about the cause(s), pathogenesis, epidemiology, and clinical manifestations of muscle disease and related neuromuscular disorders and to develop and implement strategies to examine promising therapeutic interventions.

  • A Quantitative Study on the Patient Journey and Experience in Patients with CIDP and MMN
  • Plasma Proteomics and Autoantibody Screening: a Tool for Patient Stratification and Monitoring CIDP Treatment Responses

Consortium of Independent Immunology Clinics (CIIC), 2024

September 13 - 14, 2024

Semi-annual conference of key opinion leaders in the Allergy, Asthma, and Immunology space.

Takhzyro® (lanadelumab-flyo)

  • Understanding Treatment Switching Patterns and Continuation Rates for Patients With Hereditary Angioedema Receiving Lanadelumab: Analysis of Real-World Data

Bradykinin Symposium

September 5 - 6, 2024

International experts in the field of bradykinin discuss the genetic, molecular, and cellular drivers of angioedema.

  • Comorbid Conditions in Patients With Hereditary Angioedema: Icatibant Outcome Survey

American Association of Nurse Practitioners (AANP), 2024

June 25 - 30, 2024

A national conference offering exclusive continuing education, legislative policy updates, hands-on workshops, lively exhibitors, and networking opportunities for the nurse practitioner community.

Peripheral Nerve Society (PNS), 2024

June 22 - 25, 2024

The largest peripheral nerve meeting globally, offering the latest international research across specialties in peripheral neuropathy.

  • A Quantitative Study on The Patient Journey and Experience in Patients with CIDP and MMN

HyQvia® (Human Immune Globulin 10% with Recombinant Human Hyaluronidase)

  • Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% For Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Final Results from a Long-Term Safety and Tolerability Study

Association of Pulmonary Advanced Practice Providers (APAPP), 2024

June 20 - 22, 2024

The Association of Pulmonary Advanced Practice Providers (APAPP) is the first association to focus solely on advanced practice providers (APPs) working in the realm of pulmonary medicine. Join over 200 nurse practitioners and physician associates for in-depth reviews and discussions highlighting the latest developments and current concepts in pulmonary, critical care, and sleep medicine.

  • Overcoming Racial and Ethnic Biases in The Diagnosis of Patients with Alpha-1 Antitrypsin Deficiency in The United States Using a Machine-Learning Model

European Academy of Allergy & Clinical Immunology (EAACI), 2024

May 31 - June 3, 2024

The flagship meeting of the EAACI and the world’s largest congress specializing in the field of allergy and clinical immunology.

Eastern Allergy Conference (EAC), 2024

May 30 - June 2, 2024

Regional annual conference discussing the most current information from top experts in allergy, asthma, and immunology.

American Thoracic Society (ATS), 2024

May 17 - 22, 2024

International conference showcasing the latest advances in pulmonary disease, critical illness, and sleep disorders for scientists and clinicians at all stages of their careers.

Professional Society for Health Economics and Outcomes Research (ISPOR), 2024

May 5 - 8, 2024

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Clinical Immunology Society (CIS), 2024

May 1 - 4, 2024

Annual meeting with the goal of providing a stimulating forum with presentations and discussions on the latest advances in clinical immunology, including primary immunodeficiencies and immune dysregulatory diseases.

Academy of Managed Care Pharmacy (AMCP), 2024

April 15 - 18, 2024

Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy, offering immersive education sessions and keynote presentations.

Takhzyro® (lanadelumab-flyo)

  • Comparison of Real-World Healthcare Resource Utilization and Costs Among Patients With Hereditary Angioedema on Lanadelumab or Berotralstat Long-Term Prophylaxis

American Academy of Neurology (AAN), 2024

April 13 - 18, 2024

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

HyQvia® (Human Immune Globulin 10% with Recombinant Human Hyaluronidase)

  • Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study
  • Infusion-related Costs for HyQvia Compared to Hizentra in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Patient-reported outcomes with hyaluronidase-facilitated subcutaneous immunoglobulin 10% maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy

National Home Infusion Association (NHIA), 2024

March 23 - 27, 2024

Annual conference ideal for infusion professionals or those seeking opportunities in the industry to come together and explore the latest trends in offering home-based services.

Hereditary Angioedema International (HAEi), 2024

March 15 - 17, 2024

Every second year HAEi gathers HAE patients, caregivers, healthcare professionals, and industry representatives with a sole focus of sharing experience and knowledge on HAE topics.

Annual Meeting American Academy of Allergy Asthma and Immunology (AAAAI), 2024

February 23 - 26, 2024

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

  • Patient-Reported Outcomes Among Patients With Hereditary Angioedema Within Underrepresented Racial or Ethnic Groups

Takhzyro® (lanadelumab-flyo)

  • Real-World Treatment Outcomes in Patients With Hereditary Angioedema Receiving Lanadelumab or Other Long-Term Prophylaxis
  • Understanding the Impact of Long-Term Prophylaxis Switches for Patients With Hereditary Angioedema
  • Real-World Treatment Outcomes of Lanadelumab in the Prevention of Hereditary Angioedema Attacks: An Interim Analysis of a Polish Prospective, Multicenter, Observational Study (CHOPIN)
  • Real-World Treatment Patterns and Characteristics of Patients With Hereditary Angioedema Treated With Lanadelumab: Results From a US Retrospective Chart Review Study
  • Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada: Final Data From the EMPOWER Study
  • Burden of Illness in Adult Patients With Controlled and Poorly Controlled Hereditary Angioedema: Findings From a Multinational Survey
  • Burden of Illness in Female and Male Adult Patients With Hereditary Angioedema: Findings From a Multinational Survey and the HELP OLE Study
  • Lanadelumab Effectiveness and Safety in Adolescent Patients With Hereditary Angioedema Aged 12 to <18 Years: Pooled Results From the Real-World ENABLE and EMPOWER Studies

Western Society of Allergy, Asthma and Immunology (WSAAI), 2024

February 4 - 8, 2024

Annual scientific session uniting allergists, immunologists, nurses, and physician assistants aimed at maintaining the highest standard of practice in allergy care.

  • Understanding Social Determinants of Health and Outcomes in Patients With Hereditary Angioedema in the United States
  • Quality of Life Among Patients With Hereditary Angioedema Within Underrepresented Racial or Ethnic Groups

Takhzyro® (lanadelumab-flyo)

  • Real-World Quality of Life in Patients With HAE Receiving Lanadelumab or Other Long-Term Prophylaxis

Videos

 

Watch videos focused on Alpha-1 Antitrypsin Deficiency (AATD).

AATD Mechanism of Disease

Learn about Alpha-1 Antitrypsin Deficiency (AATD) mechanism of disease in this animated video.